Bio-Rad Laboratories Inc. Class A

548.74-0.3800-0.07%Vol 70.24K1Y Perf -28.36%
Aug 12th, 2022 16:03 DELAYED
BID399.98 ASK688.59
Open553.89 Previous Close548.74
Pre-Market- After-Market548.74
 - -  - -%
Target Price
776.67 
Analyst Rating
Strong Buy 1.00
Potential %
41.54 
Finscreener Ranking
★★★★+     56.18
Insiders Trans % 3/6/12 mo.
-/-/-100 
Value Ranking
★★★     50.49
Insiders Value % 3/6/12 mo.
-/-/-100 
Growth Ranking
★★★     50.71
Insiders Shares Cnt. % 3/6/12 mo.
-/-/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
23.27 
Earnings Rating
Sell
Market Cap16.30B 
Earnings Date
28th Jul 2022
Alpha0.01 Standard Deviation0.09
Beta0.93 

Today's Price Range

542.32556.32

52W Range

462.61832.70

5 Year PE Ratio Range

4.30288.30

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
1.68%
1 Month
9.93%
3 Months
9.29%
6 Months
-12.87%
1 Year
-28.36%
3 Years
68.20%
5 Years
154.18%
10 Years
437.03%

TickerPriceChg.Chg.%
BIO548.74-0.3800-0.07
AAPL172.123.63002.15
GOOG122.652.83002.36
MSFT291.914.89001.70
XOM94.000.81000.87
WFC45.940.69001.52
JNJ165.30-1.8400-1.10
FB196.640.99000.51
GE79.931.03001.31
JPM122.131.99001.66
 
ProfitabilityValueIndustryS&P 500US Markets
57.10
-90.40
-85.80
-3.40
-67.66
RevenueValueIndustryS&P 500US Markets
2.87B
116.55
8.24
6.41
Earnings HistoryEstimateReportedSurprise %
Q02 20222.463.3837.40
Q01 20222.804.9476.43
Q04 20212.873.2111.85
Q03 20212.303.7161.30
Q02 20211.903.5486.32
Q01 20212.505.21108.40
Q04 20203.104.0129.35
Q03 20201.853.0062.16
Earnings Per EndEstimateRevision %Trend
6/2022 QR2.46-28.28Negative
9/2022 QR3.21-15.53Negative
12/2022 FY14.202.90Positive
12/2023 FY15.650.64Positive
Next Report Date-
Estimated EPS Next Report2.46
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume70.24K
Shares Outstanding29.70K
Shares Float21.08M
Trades Count4.45K
Dollar Volume38.45M
Avg. Volume147.29K
Avg. Weekly Volume118.51K
Avg. Monthly Volume150.74K
Avg. Quarterly Volume172.60K

Bio-Rad Laboratories Inc. Class A (NYSE: BIO) stock closed at 548.74 per share at the end of the most recent trading day (a -0.07% change compared to the prior day closing price) with a volume of 70.24K shares and market capitalization of 16.30B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 8000 people. Bio-Rad Laboratories Inc. Class A CEO is Norman Schwartz.

The one-year performance of Bio-Rad Laboratories Inc. Class A stock is -28.36%, while year-to-date (YTD) performance is -27.37%. BIO stock has a five-year performance of 154.18%. Its 52-week range is between 462.61 and 832.7, which gives BIO stock a 52-week price range ratio of 23.27%

Bio-Rad Laboratories Inc. Class A currently has a PE ratio of -8.30, a price-to-book (PB) ratio of 1.83, a price-to-sale (PS) ratio of 4.71, a price to cashflow ratio of 34.00, a PEG ratio of 2.32, a ROA of -13.97%, a ROC of -17.71% and a ROE of -18.93%. The company’s profit margin is -67.66%, its EBITDA margin is -85.80%, and its revenue ttm is $2.87 Billion , which makes it $116.55 revenue per share.

Of the last four earnings reports from Bio-Rad Laboratories Inc. Class A, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $2.46 for the next earnings report. Bio-Rad Laboratories Inc. Class A’s next earnings report date is -.

The consensus rating of Wall Street analysts for Bio-Rad Laboratories Inc. Class A is Strong Buy (1), with a target price of $776.67, which is +41.54% compared to the current price. The earnings rating for Bio-Rad Laboratories Inc. Class A stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Bio-Rad Laboratories Inc. Class A has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Bio-Rad Laboratories Inc. Class A has a Buy technical analysis rating based on Technical Indicators (ADX : 9.34, ATR14 : 18.63, CCI20 : 57.32, Chaikin Money Flow : 0.07, MACD : 9.87, Money Flow Index : 67.73, ROC : 0.38, RSI : 50.99, STOCH (14,3) : 57.53, STOCH RSI : 0.99, UO : 47.66, Williams %R : -42.47), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Bio-Rad Laboratories Inc. Class A in the last 12-months were: Ajit Ramalingam (Option Excercise at a value of $0), Ajit Ramalingam (Sold 518 shares of value $278 166 ), Andrew J. Last (Option Excercise at a value of $598 480), Andrew J. Last (Sold 2 000 shares of value $1 626 203 ), Annette Tumolo (Option Excercise at a value of $1 799 043), Annette Tumolo (Sold 6 946 shares of value $5 233 746 ), Dara Wright (Option Excercise at a value of $0), Ilan Daskal (Option Excercise at a value of $283 122), Ilan Daskal (Sold 810 shares of value $668 537 ), Michael Crowley (Option Excercise at a value of $0), Norman Schwartz (Option Excercise at a value of $3 702 220), Timothy S. Ernst (Option Excercise at a value of $0)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (100.00 %)
2 (100.00 %)
2 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Bio-Rad Laboratories Inc. Class A

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (60% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the United States (40% of 2020 sales), Europe (34%), and Asia (21%), with Canada and Latin America accounting for the bulk of the remaining 5%. Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.

CEO: Norman Schwartz

Telephone: +1 510 724-7000

Address: 1000 Alfred Nobel Drive, Hercules 94547, CA, US

Number of employees: 8 000

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

56%44%

Bearish Bullish

62%38%

Bearish Bullish

58%42%

TipRanks News for BIO


News

Stocktwits